Minor
Orally Administered VX-01
Enrollment closed, study ongoing
Also in this update: Primary completion pushed from Mar 2027 to Jul 2027; Study completion pushed from Mar 2027 to Oct 2027
Vantage Biosciences LtdPhase 2 NCT06770933 Registry history of NCT06770933 on ClinicalTrials.gov (opens the registry)